Akrevia Therapeutics Launches with $30M Series A Financing Led by F-Prime Capital Partners and Atlas Venture Tim Clackson, Ph.D., former President of R&D at ARIAD Pharmaceuticals, joins as President and EVP of R&D Nessan Bermingham, Ph.D., former President & CEO of Intellia Therapeutics joins as Executive Chairman Company applies validated platform technology to develop pipeline of potent, tumor-targeted immunotherapies CAMBRIDGE, Mass., September 27, 2018-- Akrevia Therapeutics, a privately-held biopharmaceutical company focused on developing highly-potent, tumor-targeted immuno-oncology therapeutics, today announced the closing of a $30 million Series A financing led by F-Prime Capital Partners and Atlas Venture.